Anderson S D, Rodwell L T, Du Toit J, Young I H
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Chest. 1991 Nov;100(5):1254-60. doi: 10.1378/chest.100.5.1254.
Beta-adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the beta-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 micrograms) or albuterol (200 micrograms) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load +/- 1 SD was 174 +/- 47 W, ventilation (VE) was 77.9 percent +/- 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 +/- 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA--percentage of fall in FEV1, 17 +/- 12 after salmeterol; percentage of fall in FEV1, 15 +/- 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p less than 0.01) after salmeterol compared with albuterol. At 6.5 hours, the percentage of fall in FEV1 was 20 +/- 10 after salmeterol and 36 +/- 12 after albuterol. Salmeterol also had a more prolonged action as a bronchodilator and values for FEV1 were significantly higher compared with those on albuterol at 4.5 and 6.5 hours. At 6.5 hours, the FEV1 percent predicted was 96 +/- 10 after salmeterol and 84 +/- 12 after albuterol (p less than 0.01). We conclude that the extent of protection against EIA and the bronchodilation induced by both drugs was similar, but that salmeterol has a longer duration of action compared with albuterol. The reason for its superior duration of action may be due to a slower clearance of the drug from the airways.
β - 肾上腺素能受体激动剂如沙丁胺醇,在运动前即刻以气雾剂形式给药时,对预防运动诱发的哮喘(EIA)非常有效。然而,它们对EIA的保护持续时间通常小于2小时。这可能部分归因于它们从气道的快速清除。沙美特罗是一种高度亲脂性化合物,被认为可与β - 受体附近的外受体结合。本研究的目的是比较沙美特罗与沙丁胺醇对EIA的保护作用。在给予活性药物后0.5、2.5、4.5和6.5小时进行运动。受试者在六周内的四天到实验室,以8分钟的时间呼吸干燥压缩空气进行骑行。我们研究了17名年龄在19至49岁之间、患有中度至重度EIA的哮喘患者。沙美特罗(50微克)或沙丁胺醇(200微克)通过定量吸入器经储雾罐(Volumatic)给药。在对照日,平均工作负荷±1标准差为174±47瓦,通气量(VE)为目标通气量(最大自主通气量[MVV]的60%)的77.9%±11.2%,心率为每分钟170±14次。所有测试均维持此强度。在运动前后测量第一秒用力呼气容积(FEV1),并表示为预测值的百分比以及运动前值的百分比(下降百分比)。治疗后30分钟,两种药物均能有效抑制EIA——沙美特罗给药后FEV1下降百分比为17±12;沙丁胺醇给药后FEV1下降百分比为15±15。在2.5、4.5和6.5小时,与沙丁胺醇相比,沙美特罗给药后FEV1的降低明显较少(p<0.01)。在6.5小时,沙美特罗给药后FEV1下降百分比为20±10,沙丁胺醇给药后为36±12。沙美特罗作为支气管扩张剂的作用也更持久,在4.5和6.5小时时,其FEV1值与沙丁胺醇相比显著更高。在6.5小时,沙美特罗给药后FEV1预测值百分比为96±10,沙丁胺醇给药后为84±12(p<0.01)。我们得出结论,两种药物对EIA的保护程度以及诱导支气管扩张的程度相似,但与沙丁胺醇相比,沙美特罗的作用持续时间更长。其作用持续时间更优的原因可能是药物从气道清除较慢。